Outcomes of a GnRH Agonist Trigger Following a GnRH Antagonist or Flexible Progestin-Primed Ovarian Stimulation Cycle.

GnRH antagonist LH surge Progestin primed ovarian stimulation agonist trigger assisted reproduction luteinising hormone ovarian stimulation progestin

Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2022
Historique:
received: 17 12 2021
accepted: 31 03 2022
entrez: 6 6 2022
pubmed: 7 6 2022
medline: 9 6 2022
Statut: epublish

Résumé

A suggested explanation for the pituitary-suppressive effects of progestin-primed ovarian stimulation cycles (PPOS) is pituitary luteinizing hormone (LH) depletion with progestin exposure during the follicular phase. The GnRH agonist (GnRHa) trigger releases endogenous LH from the pituitary, and if the LH depletion theory is correct, the response to the agonist trigger would be dampened in PPOS cycles. In this study, we compared the performance of the GnRHa trigger after PPOS and GnRH antagonist ovarian stimulation cycles. All women who underwent ovarian stimulation with the GnRH antagonist or flexible PPOS (fPPOS) and received a GnRH agonist trigger were eligible for inclusion. Outcomes included number of metaphase-II (MII) oocytes retrieved per cycle, rates of empty follicle syndrome, maturation, fertilization, blastulation, and cumulative clinical pregnancy per stimulation cycle. During the screening period, there were 166 antagonists and 58 fPPOS cycles triggered with a GnRH agonist. Groups were matched for potential confounders using propensity score matching. Progestin-downregulated cycles had 19% high mature oocyte yield (median: 14 vs. 19 MII oocytes, P = 0.03). Cumulative ongoing pregnancy or live birth rates were estimated after matching for transferred embryo count, and rates were similar between GnRH antagonist and fPPOS group (57.0% vs. 62.1%, P = 0.68). However, the number of remaining blastocysts was higher in the fPPOS group (median: 5.0 vs. 6.0, P < 0.001). LH levels were higher in fPPOS cycles compared to GnRH antagonist cycles up to the trigger day (P < 0.001). After the GnRHa trigger, fPPOS cycles were associated with a steeper LH surge compared with antagonist cycles (P = 0.02). Higher endogenous gonadotropin levels through the stimulation period and an LH surge of higher magnitude following a GnRHa trigger suggest a milder pituitary suppression by fPPOS, which needs to be confirmed in larger samples. It appears that progestins do not deplete pituitary LH reserves and a GnRHa trigger is usable after PPOS in women with high ovarian reserve.

Identifiants

pubmed: 35663329
doi: 10.3389/fendo.2022.837880
pmc: PMC9161281
doi:

Substances chimiques

Hormone Antagonists 0
Progestins 0
Gonadotropin-Releasing Hormone 33515-09-2
Luteinizing Hormone 9002-67-9

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

837880

Informations de copyright

Copyright © 2022 Kalafat, Turkgeldi, Yıldız, Dizdar, Keles and Ata.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Front Endocrinol (Lausanne). 2019 Nov 22;10:796
pubmed: 31824419
Hum Reprod. 2020 Dec 1;35(12):2660-2662
pubmed: 33011785
Fertil Steril. 2021 Jul;116(1):130-137
pubmed: 33812651
Hum Reprod Update. 2021 Jan 4;27(1):48-66
pubmed: 33016316
Fertil Steril. 2017 Feb;107(2):379-386.e4
pubmed: 27865446
Fertil Steril. 2019 Oct;112(4):677-683
pubmed: 31371053
Fertil Steril. 2017 Sep;108(3):505-512.e2
pubmed: 28697910
Hum Reprod. 2008 Oct;23(10):2346-51
pubmed: 18583332
Gynecol Endocrinol. 2019 Oct;35(10):884-889
pubmed: 31081407
Hum Fertil (Camb). 2022 Apr;25(2):306-312
pubmed: 32672129
Fertil Steril. 2020 May;113(5):923-924
pubmed: 32059812
Reprod Biomed Online. 2020 Aug;41(2):248-253
pubmed: 32532668
Arch Gynecol Obstet. 2018 Sep;298(3):663-671
pubmed: 30069600

Auteurs

Erkan Kalafat (E)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey.
Department of Statistics, Faculty of Arts and Sciences, Middle East Technical University, Ankara, Turkey.

Engin Turkgeldi (E)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey.

Sule Yıldız (S)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey.

Merve Dizdar (M)

Department of Obstetrics and Gynecology, Umraniye Teaching and Research Hospital, Istanbul, Turkey.

Ipek Keles (I)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey.

Baris Ata (B)

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Koc University School of Medicine, Istanbul, Turkey.
ART Fertility Clinics, Dubai, United Arab Emirates.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH